ArticleBMC complementary medicine and therapies2025
Treatment of rheumatoid arthritis by Rhododendron molle G. Don: the anti-inflammatory mechanism of its extract was elucidated by network analysis combined with experimental verification.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review ofFrontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe investigated the underlying mechanism by which Rhododendron molle G. Don extraction (RME) mitigates rheumatoid arthritis (RA) in rats through network analysis and molecular docking.
methodsThe active metabolites of RME were analyzed by high performance liquid chromatography - evaporative light scattering detector (HPLC-ELSD). Subsequently, the potential targets were screened from various databases. Genes relative to RA and GSE55457 data sets were obtained. Furthermore, the biological processes associated with the drug targets and GSE55457 genes were analyzed. A protein - protein interaction (PPI) network was constructed and subjected to topological analysis. Key proteins within this network were identified and validated by in vivo experiments.
resultsHPLC analysis showed that REM contained multiple anti-inflammatory active metabolites. Through network analysis, we found that the potential target of the drug and the differential genes of RA were involved in several signaling pathways, including Wnt, JAK-STAT and other signaling pathways which are known to play important roles in inflammatory responses. Dvl1 and GSK-3β were screened as the core targets by topological analysis of the potential target protein interaction network. The results of molecular docking showed that the core target had good affinity with the active metabolites of R. molle. It was confirmed that RME could remarkably downregulate the expression of Dvl1, Wnt1, p-GSK-3β, leading to a marked reduction in toe thickness and arthritis index (AI) of AIA rats, reducing the level of inflammatory factors, and alleviating the degree of tail ulceration in AIA rats in a dose-dependent manner, displaying therapeutic effects comparable to those of Tripterygium wilfordii polyglycoside tablets.
conclusionRME contains active metabolites with anti-inflammatory effects, which can significantly inhibit inflammation through multiple targets and pathways to effectively ameliorate RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.